These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17189015)

  • 21. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of erythropoietin in predialysis patients.
    Anderson S
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):103-6. PubMed ID: 2024665
    [No Abstract]   [Full Text] [Related]  

  • 24. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 25. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 26. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients.
    Zehnder C
    Nephron; 1989; 51(3):424-5. PubMed ID: 2918959
    [No Abstract]   [Full Text] [Related]  

  • 27. Association between haemoglobin and neopterin concentrations in haemodialysis patients treated with erythropoietin.
    Diez-Ruiz A; Weiss G; Artner-Dworzak E; Dittrich PV; Wachter H; Fuchs D
    Eur J Haematol; 1993 Sep; 51(3):175-6. PubMed ID: 8405333
    [No Abstract]   [Full Text] [Related]  

  • 28. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 29. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
    Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
    Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of angiotensin-converting enzyme inhibitors on anemia in hemodialyzed patients.
    Teruel JL; Fernandez Juarez G; Marcen R; Nogueira J; Ortuño J
    Nephron; 1996; 73(1):113. PubMed ID: 8742977
    [No Abstract]   [Full Text] [Related]  

  • 33. A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate.
    Walker RG; Strippoli GF
    Lancet; 2007 Oct; 370(9596):1395-6. PubMed ID: 17950848
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating levels of thrombopoietin and erythropoietin in hemodialysis patients.
    Otsubo Y; Nitta K; Otsubo S; Kimata N; Miwa N; Watanabe Y; Uchida K; Kawashima A; Yumura W; Akiba T; Nihei H
    Acta Haematol; 2003; 109(4):209-11. PubMed ID: 12853697
    [No Abstract]   [Full Text] [Related]  

  • 36. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 37. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M; Gomez-Campdera F; Polo JR; Tejedor A; Ruiz MA; Vazquez I; Verde E; Valderrabano F
    Clin Nephrol; 1996 Jun; 45(6):420-1. PubMed ID: 8793241
    [No Abstract]   [Full Text] [Related]  

  • 38. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 39. Does erythropoietin cause epilepsy.
    Cengiz K; Işlek I
    Nephron; 1996; 73(2):320-1. PubMed ID: 8773367
    [No Abstract]   [Full Text] [Related]  

  • 40. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.